| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Inhibrx Biosciences, Inc. (INBX) has 5 insiders with recent SEC Form 4 filings, including 9 buys and 0 sells. INBX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| ? | 102.9K | $11.38M | - | |
| Dir | 15.0K | $1.66M | - | |
| Dir | 15.0K | $1.66M | - | |
| Dir | 15.0K | $1.66M | - | |
| Dir | 15.0K | $1.66M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2024 | Lappe Mark87 | Chief Executive Officer | Buy | 40,000 | $12.96 | $518,282.20 | +70.4% | +9.5% | +85.1% | |
| Jun 5, 2024 | Kayyem Jon Faiz51 | Director | Buy | 57,549 | $17.32 | $997,024.17 | +2.6% | -5.6% | -23.7% | |
| Jun 4, 2024 | Kayyem Jon Faiz51 | Director | Buy | 286,786 | $17.18 | $4,927,579.86 | +6.1% | -7.3% | -24.5% |